Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
| ▸ | MRGPRX1 | Q96LB2 | 4/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26564738 | 0.87 | CHRNB2 (0.44) | NPC1RAB9ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26564742 | 0.78 | CHRNB2 (0.43) | NPC1RAB9ARXFP1CHRNB2CHRNB4 | |
| SCHEMBL26564737 | 0.74 | NPC1 (0.50) | NPC1RAB9ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24335751 | 0.70 | NPC1 (0.53) | NPC1RAB9ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31722789 | 0.70 | NPC1 (0.61) | NPC1RAB9ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL29575361 | 0.70 | NPC1 (0.61) | NPC1RAB9ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2743115 | 0.70 | NPC1 (0.61) | NPC1RAB9ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24335455 | 0.70 | RXFP1 (0.60) | NPC1RAB9ARXFP1CHRNB2CHRNB4 | |
| SCHEMBL26564714 | 0.68 | TRPV1 (0.48) | NPC1RAB9ARXFP1KDM4EMEN1 | |
| SCHEMBL17774884 | 0.66 | NPC1 (0.63) | NPC1RAB9ACHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331663-A1 | SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS | THE CLEVELAND CLINIC FOUNDATION | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331663-A1 | SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS | NQO1, NADK, CD38 | NPC1 556/4885RAB9A 1251/4885RXFP1 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.